COMMUNIQUÉS West-GlobeNewswire

Hua Medicine – Business & Pipeline Update
05/06/2019
Trial Products Exploratory NDA Enabling Description / Indication HMM0301 Dorzagliatin (HMS5552) Phase III ongoing Drug-naïve T2D HMM0302 Dorzagliatin + Metformin Phase III ongoing Metformin tolerant T2D New HMM0303 [...]
Reata Announces Presentations at the 56th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA)
05/06/2019
IRVING, Texas, June 04, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that four abstracts highlighting Reata’s progress in developing [...]
Sientra Announces Pricing of Upsized Public Offering of Common Stock
05/06/2019
SANTA BARBARA, Calif., June 04, 2019 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced the upsizing and pricing of its previously announced [...]
INmune Bio to present Alzheimer’s Drug Candidate XPro1595 at The TNF Conference
04/06/2019
LA JOLLA, Calif., June 04, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB ), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today [...]
Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
04/06/2019
CAMBRIDGE, Mass., June 04, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the [...]
Genfit: GENFIT Launches a Phase 2 Trial Evaluating Elafibranor on Hepatic Lipid Composition for NAFL
04/06/2019
GENFIT Launches a Phase 2 Trial Evaluating Elafibranor on Hepatic Lipid Composition for NAFL Study objective to determine the effect of elafibranor, a dual PPAR alpha/delta agonist, on fatty acid saturation Phase 2 [...]
Genfit: GENFIT lance un essai de Phase 2 évaluant l’effet d’elafibranor sur la composition lipidique du foie dans la stéatose hépatique
04/06/2019
GENFIT lance un essai de Phase 2 évaluant l’effet d’elafibranor sur la composition lipidique du foie dans la stéatose hépatique L’étude a pour objectif de déterminer l’effet d’elafibranor, un double agoniste des PPAR [...]
BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04/06/2019
RESEARCH TRIANGLE PARK, N.C., June 04, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst’s board of directors granted four newly-hired [...]
Novavax CFO John Trizzino to Discuss Future of Influenza Vaccines on Industry Panel at 2019 BIO International Convention
04/06/2019
GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial Officer, will join other vaccine [...]
Silk Road Medical Announces Key TCAR Presentations at the Society for Vascular Surgery 2019 Vascular Annual Meeting
04/06/2019
Results Include Data from SVS TCAR Surveillance Project and ROADSTER-2 Study SUNNYVALE, Calif. , June 04, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke [...]
Emergent BioSolutions Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine
04/06/2019
GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced approval by the U.S. Food and Drug Administration (FDA) of the Prior Approval Supplement (PAS) submitted by the [...]
HealthEquity Reports First Quarter Ended April 30, 2019 Financial Results
04/06/2019
Highlights of the first quarter include: Revenue of $87.1 million, an increase of 25% compared to Q1 FY19. Net income of $41.8 million, compared to $22.6 million in Q1 FY19. Includes $17.9 million, net of tax ($23.5 [...]
TG Therapeutics Presents Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting
04/06/2019
Overall response rate (ORR) of 52% (N=42), with complete response (CR) rate of 19%, by central independent review committee (IRC) Umbralisib was well tolerated with a safety profile that appeared to be maintained with [...]
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
04/06/2019
SAN DIEGO and TORONTO, June 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the [...]
Affimed Announces Annual General Meeting of Shareholders
04/06/2019
Heidelberg, Germany, June 04, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancers, announced today that the Annual [...]
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/06/2019
DUBLIN, Ireland, June 04, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today [...]
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock
04/06/2019
CRANBURY, N.J., June 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the closing of its previously announced offering of common stock. The Company issued a total of 18,720,930 shares of [...]
XBiotech Announces Closing of Public Offering of Common Shares
04/06/2019
AUSTIN, Texas, June 04, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced the closing of its previously announced underwritten public offering of 4,848,485 of its common shares at a public offering [...]
AB Science is providing a summary of the web conference held on 4 June 2019
04/06/2019
Paris, 4 June 2019, 8pm AB Science outlook for 2019 - Summary of webcast part 1 AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization [...]

Pages